About Cabling Installation & Maintenance

Our mission: Bringing practical business and technical intelligence to today's structured cabling professionals

For more than 30 years, Cabling Installation & Maintenance has provided useful, practical information to professionals responsible for the specification, design, installation and management of structured cabling systems serving enterprise, data center and other environments. These professionals are challenged to stay informed of constantly evolving standards, system-design and installation approaches, product and system capabilities, technologies, as well as applications that rely on high-performance structured cabling systems. Our editors synthesize these complex issues into multiple information products. This portfolio of information products provides concrete detail that improves the efficiency of day-to-day operations, and equips cabling professionals with the perspective that enables strategic planning for networks’ optimum long-term performance.

Throughout our annual magazine, weekly email newsletters and 24/7/365 website, Cabling Installation & Maintenance digs into the essential topics our audience focuses on.

  • Design, Installation and Testing: We explain the bottom-up design of cabling systems, from case histories of actual projects to solutions for specific problems or aspects of the design process. We also look at specific installations using a case-history approach to highlight challenging problems, solutions and unique features. Additionally, we examine evolving test-and-measurement technologies and techniques designed to address the standards-governed and practical-use performance requirements of cabling systems.
  • Technology: We evaluate product innovations and technology trends as they impact a particular product class through interviews with manufacturers, installers and users, as well as contributed articles from subject-matter experts.
  • Data Center: Cabling Installation & Maintenance takes an in-depth look at design and installation workmanship issues as well as the unique technology being deployed specifically for data centers.
  • Physical Security: Focusing on the areas in which security and IT—and the infrastructure for both—interlock and overlap, we pay specific attention to Internet Protocol’s influence over the development of security applications.
  • Standards: Tracking the activities of North American and international standards-making organizations, we provide updates on specifications that are in-progress, looking forward to how they will affect cabling-system design and installation. We also produce articles explaining the practical aspects of designing and installing cabling systems in accordance with the specifications of established standards.

Cabling Installation & Maintenance is published by Endeavor Business Media, a division of EndeavorB2B.

Contact Cabling Installation & Maintenance

Editorial

Patrick McLaughlin

Serena Aburahma

Advertising and Sponsorship Sales

Peter Fretty - Vice President, Market Leader

Tim Carli - Business Development Manager

Brayden Hudspeth - Sales Development Representative

Subscriptions and Memberships

Subscribe to our newsletters and manage your subscriptions

Feedback/Problems

Send a message to our general in-box

 

Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies

Immunome (Nasdaq: IMNM), a biopharmaceutical company specializing in antibody therapeutics, and Morphimmune, a biotech firm known for targeted oncology therapeutics, have entered into a definitive merger agreement. This merger is expected to create a synergistic platform for developing best-in-class targeted cancer therapies across multiple modalities.

Immunome: New Leadership and Investment

Following the merger, the company will operate under the name Immunome and will be led by Morphimmune’s current President & CEO, Dr. Clay B. Siegall, who is also the former co-founder & CEO of Seagen, Inc. His past achievements include earning FDA approvals for four cancer therapies and overseeing Seagen’s acquisition by Pfizer, Inc. for $43 billion.

A concurrent private placement investment of $125 million will further fund the development of Immunome’s combined pipeline, with the intent to submit three Investigational New Drug Applications (INDs) within 18 months of closing.

Locations and Future Plans

Immunome will retain its original ticker symbol and be headquartered in Seattle, WA, with research lab facilities in Exton, PA and West Lafayette, IN. The combined pipeline of the new entity includes a novel anti-IL-38 mAb derived from Immunome’s discovery engine, as well as a folate receptor-targeted TLR7 agonist (FA-TLR7a) and FAP-targeted radioligand (177Lu-FAP).

The company also intends to explore opportunities for strategic in-licensing and further acquisitions. “Combining Morphimmune’s Targeted Effector Platform with Immunome’s Discovery Engine will enable us to pursue novel targets and modalities, unlocking substantial synergistic value,” Dr. Siegall stated.

About the Merger

Immunome will acquire Morphimmune through a tax-free reorganization. After the merger, existing Immunome shareholders will own approximately 55% of the combined company, and Morphimmune shareholders will hold around 45%. The transaction is expected to close by the end of Q4 2023, pending customary closing conditions.

In line with the merger, Dr. Siegall has signed an employment agreement with Immunome and will be granted a stock option for up to 2,137,080 shares of Immunome common stock.

Board of Directors and Advisory Teams

The Board of Directors of the merged entity will include two members selected by Morphimmune, one selected by Immunome, and four independent directors. James P. Boylan, Chief Executive Officer of Enavate Sciences, will join the Board of Directors following the private placement.

Immunome is advised by Stifel as a financial advisor and Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. as legal counsel. Morphimmune is being advised by TD Cowen as a financial advisor and Cooley LLP as legal counsel. TD Cowen and SVB Securities are serving as placement agents for the private placement.

Disclosure: No position. Spotlight Growth has no relationships with any of the companies mentioned in this article and did not receive payment in any form for its creation. This is an opinion article and is not meant to be financial advise. We are not broker-dealers or investment professionals. Please conduct your own due diligence. For more information on our disclosures, please visit: https://spotlightgrowth.com/disclosures/

The post Immunome (NASDAQ: IMNM) and Morphimmune Announce Merger to Develop Best-in-Class Targeted Cancer Therapies appeared first on Spotlight Growth.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.